X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3626) 3626
Publication (452) 452
Newsletter (116) 116
Book Review (94) 94
Book Chapter (16) 16
Book / eBook (7) 7
Conference Proceeding (5) 5
Magazine Article (5) 5
Dissertation (4) 4
Data Set (1) 1
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3079) 3079
index medicus (2302) 2302
pharmacology & pharmacy (1974) 1974
male (1724) 1724
cytochrome p-450 (1609) 1609
female (1455) 1455
pharmacokinetics (1089) 1089
adult (1075) 1075
genotype (1070) 1070
middle aged (1017) 1017
metabolism (945) 945
drug interactions (874) 874
cytochrome p-450 enzyme system - metabolism (793) 793
cytochrome p-450 cyp2c19 (774) 774
pharmacogenetics (772) 772
aryl hydrocarbon hydroxylases - genetics (742) 742
aged (669) 669
physiological aspects (597) 597
genetic aspects (581) 581
cytochrome p450 (580) 580
animals (577) 577
polymorphism, genetic (571) 571
analysis (566) 566
research (527) 527
cyp2c19 (511) 511
metabolites (476) 476
ticlopidine - analogs & derivatives (461) 461
pharmacology/toxicology (449) 449
polymorphism (449) 449
cytochrome p-450 enzyme system - genetics (445) 445
clopidogrel (442) 442
enzymes (434) 434
in-vitro (432) 432
pharmacology (396) 396
young adult (381) 381
area under curve (378) 378
genetic polymorphisms (368) 368
toxicology (366) 366
phenotype (345) 345
aryl hydrocarbon hydroxylases - metabolism (343) 343
human liver-microsomes (339) 339
cytochrome p-450 cyp2c19 - genetics (328) 328
cytochrome p-450 cyp2d6 - genetics (317) 317
alleles (315) 315
drug therapy (314) 314
dose-response relationship, drug (307) 307
medicine & public health (299) 299
treatment outcome (297) 297
omeprazole (292) 292
cyp2d6 (290) 290
inhibition (289) 289
care and treatment (279) 279
biomedicine (265) 265
drug metabolism (265) 265
proton pump inhibitors (260) 260
cross-over studies (258) 258
health aspects (256) 256
platelet aggregation inhibitors - therapeutic use (255) 255
adolescent (252) 252
cytochrome p-450 cyp3a - metabolism (252) 252
cytochrome (244) 244
administration, oral (240) 240
p-glycoprotein (240) 240
drugs (239) 239
ticlopidine - therapeutic use (239) 239
mixed function oxygenases - genetics (236) 236
internal medicine (234) 234
dosage and administration (229) 229
cytochrome p-450 cyp2c9 (223) 223
polymorphism, single nucleotide (223) 223
risk factors (222) 222
liver (220) 220
polymorphisms (217) 217
cytochrome p-450 cyp2d6 - metabolism (216) 216
therapy (214) 214
microsomes, liver - metabolism (213) 213
rats (211) 211
biotransformation (210) 210
cancer (204) 204
percutaneous coronary intervention (201) 201
cytochrome p-450 enzyme inhibitors (194) 194
article (191) 191
biochemistry & molecular biology (189) 189
aged, 80 and over (186) 186
oncology (183) 183
cyp2c9 (180) 180
hydroxylation (179) 179
cyp3a4 (174) 174
pharmacodynamics (173) 173
gene frequency (172) 172
platelet aggregation - drug effects (171) 171
drug therapy, combination (170) 170
abridged index medicus (168) 168
expression (166) 166
half-life (166) 166
enzyme inhibitors - pharmacology (164) 164
identification (164) 164
association (163) 163
genotype & phenotype (163) 163
platelet aggregation inhibitors - pharmacology (163) 163
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3740) 3740
Russian (6) 6
Chinese (5) 5
German (5) 5
Spanish (5) 5
Japanese (4) 4
French (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 04/2015, Volume 104, Issue 4, pp. 1478 - 1491
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2009, Volume 360, Issue 4, pp. 354 - 362
The antiplatelet drug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes. This study shows that CYP polymorphisms that reduce clopidogrel... 
MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | STENT THROMBOSIS | HEALTHY-SUBJECTS | INCREASED RISK | PLATELET INHIBITION | ACUTE CORONARY SYNDROMES | PRASUGREL | ST-SEGMENT ELEVATION | INDIVIDUAL RESPONSIVENESS | ATHEROTHROMBOTIC EVENTS | Ticlopidine - pharmacology | Ticlopidine - therapeutic use | Area Under Curve | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Cardiovascular Diseases - genetics | Angioplasty, Balloon, Coronary | Ticlopidine - adverse effects | Ticlopidine - metabolism | Cardiovascular Diseases - epidemiology | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Stents | Platelet Aggregation Inhibitors - adverse effects | Genotype | Thrombosis - epidemiology | Combined Modality Therapy | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Randomized Controlled Trials as Topic | Cytochrome P-450 CYP2C19 | Acute Coronary Syndrome - therapy | Heterozygote | Thrombosis - genetics | Mutation | Usage | Genetic variation | Cytochrome P-450 | Physiological aspects | Causes of | Clopidogrel | Cardiovascular diseases | Health aspects | Risk factors | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 09/2016, Volume 119, Issue 3, pp. 284 - 290
Cytochrome P450 (CYP) activity can be assessed using a ‘cocktail’ phenotyping approach. Recently, we have developed a cocktail (Geneva cocktail) which combines... 
2D6 | PARAXANTHINE | BUPROPION | IN-VIVO | PHARMACOLOGY & PHARMACY | TOXICOLOGY | FLURBIPROFEN | METABOLIZING-ENZYMES | COOPERSTOWN 5+1 COCKTAIL | ORAL-CONTRACEPTIVES | P-GLYCOPROTEIN | Caffeine - administration & dosage | Humans | Midazolam - administration & dosage | Male | Genotyping Techniques | Cytochrome P-450 CYP2B6 - metabolism | Terfenadine - administration & dosage | Caffeine - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Cytochrome P-450 CYP3A - genetics | Dried Blood Spot Testing - methods | Cytochrome P-450 CYP1A2 - genetics | Flurbiprofen - administration & dosage | Adult | Female | Dextromethorphan - pharmacokinetics | Cytochrome P-450 CYP2C9 - metabolism | Terfenadine - pharmacokinetics | Bupropion - pharmacokinetics | Cytochrome P-450 CYP2D6 - genetics | Flurbiprofen - pharmacokinetics | Cytochrome P-450 CYP2B6 - genetics | Omeprazole - administration & dosage | Cytochrome P-450 CYP2C19 - genetics | Terfenadine - analogs & derivatives | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP1A2 - metabolism | Bupropion - administration & dosage | Cytochrome P-450 CYP2C9 - genetics | Cross-Over Studies | Phenotype | Cytochrome P-450 CYP3A - metabolism | Adolescent | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 Enzyme System - genetics | Cytochrome P-450 CYP2C19 - metabolism | Dextromethorphan - administration & dosage | Medical examination | Drug interactions | Analysis | Methods | Blood | Cytochrome P-450 | Confidence intervals | Cytochrome | Prescription drugs | Drug dosages | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2014, Volume 95, Issue 6, pp. 653 - 662
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 12/2007, Volume 5, Issue 12, pp. 2429 - 2436
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit the platelet P2Y12 adenosine diphosphate receptor. The... 
clopidogrel | P2Y12 receptor | prasugrel | platelet function | thienopyridines | cytochrome P450 enzymes | Prasugrel | Cytochrome P450 enzymes | receptor | P2Y | Platelet function | Thienopyridines | Clopidogrel | MYOCARDIAL-INFARCTION | STENT THROMBOSIS | ANTIPLATELET THERAPY | ATHEROTHROMBOTIC EVENTS | INCREASED RISK | P2Y receptor | THIENOPYRIDINE P2Y INHIBITOR | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | CORONARY-ARTERY-DISEASE | PLATELET REACTIVITY | ACTIVE METABOLITE | Cytochrome P-450 CYP2C9 | Prasugrel Hydrochloride | Ticlopidine - pharmacology | Area Under Curve | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Mixed Function Oxygenases - metabolism | Reference Values | Thiophenes - blood | Platelet Aggregation Inhibitors - blood | Receptors, Purinergic P2Y12 | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Retrospective Studies | Ticlopidine - pharmacokinetics | Piperazines - pharmacokinetics | Blood Platelets - drug effects | Piperazines - blood | Purinergic P2 Receptor Antagonists | Thiophenes - pharmacology | Genotype | Clinical Trials as Topic | Piperazines - pharmacology | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Polymorphism, Genetic | Cross-Over Studies | Thiophenes - pharmacokinetics | Phenotype | Prodrugs - pharmacokinetics | Blood Platelets - metabolism | Cytochrome P-450 CYP2C19 | Receptors, Purinergic P2 - metabolism | Mixed Function Oxygenases - genetics | Prodrugs - pharmacology | Research Design | Ticlopidine - blood | Adenosine diphosphate | Genetic aspects | Metabolites | Cytochrome P-450
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2018, Volume 74, Issue 3, pp. 285 - 296
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 61, Issue 8, pp. 872 - 879
Objectives This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and... 
Cardiovascular | Internal Medicine | pharmacokinetics | risk factors | receptors | drugs | platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | GENOTYPE | REACTIVITY | TRIAL | CIGARETTE-SMOKING | PARAOXONASE-1 | RESISTANCE | PRASUGREL | ABSORPTION | ASSOCIATION | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Drug Monitoring - methods | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Drug Therapy, Combination | Platelet Aggregation - genetics | Cardiovascular Diseases - etiology | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Platelet Function Tests - methods | Aryldialkylphosphatase - genetics | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Cross-Over Studies | Smoking - metabolism | Confounding Factors (Epidemiology) | Proton Pump Inhibitors - pharmacokinetics | Blood Coagulation - drug effects | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | ATP Binding Cassette Transporter, Sub-Family B | Cardiovascular Diseases - psychology | Patient Compliance | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Phosphates | Drugs | Prescribing | Medical colleges | Continuing medical education | Metabolites | Vasodilators | Cytochrome P-450 | Physiological aspects | Proton pump inhibitors | Genetic aspects | Patient compliance | Research institutes | Studies | Cytochrome | Body mass index | Nutrition research | Genotype & phenotype | Demographics | Drug therapy | Acute coronary syndromes | Drug dosages
Journal Article
Journal Article
Journal Article